( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients

Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766

Recurring mutations found by sequencing an acute myeloid leukemia genome

Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020

Mutation in TET2 in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035

Regulation of the HIF-1α Level Is Essential for Hematopoietic Stem Cells

Takubo, K., Goda, N., Yamada, W., Iriuchishima, H., Ikeda, E., Kubota, Y., Shima, H., Johnson, R. S., Hirao, A., Suematsu, M., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.020 · Cited by 891

Enasidenib for the treatment of acute myeloid leukemia

Dugan, J. P., & Pollyea, D. A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1477585 · Cited by 43

The Impact of Epigenetic Modifications in Myeloid Malignancies

Venney, D., Mohd-Sarip, A., & Mills, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095013 · Cited by 46

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

Ferret, Y., Boissel, N., Hélevaut, N., Madic, J., Nibourel, O., Marceau‐Renaut, A., Bucci, M., Geffroy, S., Celli‐Lebras, K., Castaigné, S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183525 · Cited by 45

Enasidenib and ivosidenib in AML

Martelli, M. P., Martino, G., Cardinali, V., Falini, B., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07024-x · Cited by 42

Targeting fuel pocket of cancer cell metabolism: A focus on glutaminolysis

Sharma, S., Agnihotri, N., & Kumar, S. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114943 · Cited by 42

Gerometabolites: The pseudohypoxic aging side of cancer oncometabolites

Menéndez, J. A., Alarcón, T., & Joven, J. (2014) · Cell Cycle · doi:10.4161/cc.28079 · Cited by 42

Metabolic Regulation of Hypoxia-Inducible Transcription Factors: The Role of Small Molecule Metabolites and Iron

Bailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41

Metabolic underpinnings of leukemia pathology and treatment

Nemkov, T. G., D’Alessandro, A., & Reisz, J. A. (2018) · Cancer Reports · doi:10.1002/cnr2.1139 · Cited by 46

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity

Chittaranjan, S., Chan, S. Y., Yang, C. P., Yang, K., Chen, V., Moradian, A., Firme, M. R., Song, J., Go, N. E., Blough, M. D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2401 · Cited by 44

Stem cell origin of myelodysplastic syndromes

Elias, H. K., Schinke, C., Bhattacharyya, S., Will, B., Verma, A. K., & Steidl, U. G. (2013) · Oncogene · doi:10.1038/onc.2013.520 · Cited by 40

L2hgdh Deficiency Accumulates l -2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration

Ma, S., Sun, R., Jiang, B., Gao, J., Deng, W., Liu, P., He, R., Cui, J., Ji, M., Yi, W., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00492-16 · Cited by 39

Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate

Zhao, M., Yao, P., Mao, Y., Wu, J., Wang, W., Geng, C., Cheng, J., Du, W., & Jiang, P. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00532-w · Cited by 40

Lactate Dehydrogenase C Produces S-2-Hydroxyglutarate in Mouse Testis

Teng, X., Emmett, M. J., Lazar, M. A., Goldberg, E., & Rabinowitz, J. D. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00290 · Cited by 39

Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications

Poinsignon, V., Mercier, L., Nakabayashi, K., David, M. D., Lalli, A., Penard‐Lacronique, V., Quivoron, C., Saada, V., de Botton, S., Broutin, S., et al. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.04.030 · Cited by 43

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

Ragon, B. K., & Dinardo, C. D. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0418-6 · Cited by 39

A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’

Bazinet, A., & Assouline, S. E. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1875814 · Cited by 39

Clinical development of IDH1 inhibitors for cancer therapy

Zarei, M., Hue, J. J., Hajihassani, O., Graor, H. J., Katayama, E., Loftus, A. W., Bajor, D. L., Rothermel, L. D., Gohar, A. V., & Winter, J. M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102334 · Cited by 39

Metabolism–epigenome crosstalk in physiology and diseases

Hino, S., Nagaoka, K., & Nakao, M. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.57 · Cited by 39

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis

Ohba, S., & Hirose, Y. (2016) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2015-0322 · Cited by 38

Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome

Budczies, J., & Denkert, C. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42118-6_7 · Cited by 39

The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas

Pisapia, D. J. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0493-ra · Cited by 43

Non‐genetic heterogeneity, altered cell fate and differentiation therapy

Lewis, A. C., & Kats, L. M. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012670 · Cited by 36

Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy

Guo, R., Li, J., Hu, J., Fu, Q., Yan, Y., Xu, S., Wang, X., & Jiao, F. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110417 · Cited by 37

D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH

Oizel, K., Gratas, C., Nadaradjane, A., Oliver, L., Vallette, F. M., & Pecqueur, C. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.13 · Cited by 38

Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context

Bi, J., Wu, S., Zhang, W., & Mischel, P. S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.05.002 · Cited by 37

Oncometabolite Fingerprinting Using Fluorescent Single‐Walled Carbon Nanotubes

Amir, D., Hendler‐Neumark, A., Wulf, V., Ehrlich, R., & Bisker, G. (2021) · Advanced Materials Interfaces · doi:10.1002/admi.202101591 · Cited by 37

Targeting the IDH2 Pathway in Acute Myeloid Leukemia

Amaya, M. L., & Pollyea, D. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0536 · Cited by 37

VEGFR2–Mediated Reprogramming of Mitochondrial Metabolism Regulates the Sensitivity of Acute Myeloid Leukemia to Chemotherapy

Pereira, S. N., Caiado, F., Carvalho, T., Matias, I., Graça, G., Gonçalves, L. G., Silva‐Santos, B., Norell, H., & Dias, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1166 · Cited by 36

Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective

van Dijk, A. D., de Bont, E. S. J. M., & Kornblau, S. M. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1717951 · Cited by 34

Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Platt, M. Y., Fathi, A. T., Borger, D. R., Brunner, A. M., Hasserjian, R. P., Balaj, L., Lum, A. M., Yip, S. S. F., Dias-Santagata, D. C., Zheng, Z., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.06.004 · Cited by 36

Advances in treating acute myeloid leukemia

Showel, M. M., & Levis, M. J. (2014) · F1000Prime Reports · doi:10.12703/p6-96 · Cited by 34

Imaging Manifestations of the Leukodystrophies, Inherited Disorders of White Matter

Yang, E., & Prabhu, S. P. (2014) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2013.11.008 · Cited by 35

Crosstalk between epigenetics and metabolism—Yin and Yang of histone demethylases and methyltransferases in cancer

Filipp, F. V. (2017) · Briefings in Functional Genomics · doi:10.1093/bfgp/elx001 · Cited by 40

Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine

Carbone, M., Amelio, I., Affar, E. B., Brugarolas, J., Cannon‐Albright, L., Cantley, L. C., Cavenee, W. K., Chen, Z. J., Croce, C. M., D’Andrea, A. D., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0213-5 · Cited by 37

Tet2 Controls the Responses of β cells to Inflammation in Autoimmune Diabetes

Rui, J., Deng, S., Perdigoto, A. L., Ponath, G. D., Kursawe, R., Lawlor, N. T., Sumida, T. S., Levine-Ritterman, M., Stitzel, M. L., Pitt, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25367-z · Cited by 36

Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis

Li, Y., Qin, Q., Zhang, Y., & Cao, Y. (2022) · Current Oncology · doi:10.3390/curroncol29100542 · Cited by 34

Concise Review: Genetic Dissection of Hypoxia Signaling Pathways in Normal and Leukemic Stem Cells

Gezer, D., Vukovic, M., Soga, T., Pollard, P. J., & Kranc, K. R. (2014) · Stem Cells · doi:10.1002/stem.1657 · Cited by 35

Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin

Biedermann, J., Preussler, M., Conde, M., Peitzsch, M., Richter, S., Wiedemuth, R., Abou‐El‐Ardat, K., Krüger, A., Meinhardt, M., Schackert, G., et al. (2019) · Cancers · doi:10.3390/cancers11122028 · Cited by 36

Optogenetics with Atomic Precision─A Comprehensive Review of Optical Control of Protein Function through Genetic Code Expansion

Charette, M. E., Rosenblum, C., Shade, O., & Deiters, A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00224 · Cited by 36

Neomorphic mutations create therapeutic challenges in cancer

Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 33

Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma

Ribeiro, M. L., Reyes-Garau, D., Armengol, M., Fernández-Serrano, M., & Roué, G. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00986 · Cited by 34

Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging

Yang, X., Xing, Z., She, D., Lin, Y., Zhang, H., Su, Y., & Cao, D. (2022) · BMC Medical Imaging · doi:10.1186/s12880-022-00832-3 · Cited by 33

Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness

Liu, A. C. H., Cathelin, S., Yang, Y., Dai, D. L., Ayyathan, D. M., Hosseini, M., Minden, M. D., Tierens, A. M., & Chan, S. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1293 · Cited by 33

Cytosine modifications in neurodevelopment and diseases

Yao, B., & Jin, P. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1433-y · Cited by 33

Deciphering the Warburg Effect: Metabolic Reprogramming, Epigenetic Remodeling, and Cell Dedifferentiation

Li, A. M., & Ye, J. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-120857 · Cited by 31

New insights into the biology of T-cell lymphomas

Iqbal, J., Inghirami, G., & Chan, W. C. (2024) · Blood · doi:10.1182/blood.2023021787 · Cited by 32

Oxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma

Her, Y. F., Nelson-Holte, M. H., & Maher, L. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127471 · Cited by 34

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions

Upadhyay, V. A., Brunner, A. M., & Fathi, A. T. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.003 · Cited by 33

The PHD1 oxygen sensor in health and disease

Kennel, K. B., Burmeister, J., Schneider, M. A., & Taylor, C. T. (2018) · The Journal of Physiology · doi:10.1113/jp275327 · Cited by 34

Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma

Iqbal, J., Amador, C., McKeithan, T. W., & Chan, W. C. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-99716-2_2 · Cited by 35

Dietary Alpha‐Ketoglutarate Promotes Epithelial Metabolic Transition and Protects against DSS‐Induced Colitis

Tian, Q., Iniguez, A. B., Sun, Q., Wang, H., Du, ‬., & Zhu, M. J. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000936 · Cited by 33

Intergenerational trauma transmission is associated with brain metabotranscriptome remodeling and mitochondrial dysfunction

Alhassen, S., Chen, S., Alhassen, L., Phan, A., Khoudari, M., Silva, A. D., Barhoosh, H., Wang, Z., Parrocha, C. M. T., Shapiro, E., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02255-2 · Cited by 37

Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells

Wilson, E. R., Helton, N., Heath, S. E., Fulton, R. S., Payton, J. E., Welch, J. S., Walter, M. J., Westervelt, P., DiPersio, J. F., Link, D. C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01476-y · Cited by 31

Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer

Chen, D., Xia, S., Wang, M., Lin, R., Li, Y., Mao, H. Z., Aguiar, M., Famulare, C. A., Shih, A. H., Brennan, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1040 · Cited by 34

The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR/Chk1 via pyrimidine depletion

Dembitz, V., Tomić, B., Kodvanj, I., Simon, J. A., Bedalov, A., & Višnjić, D. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009396 · Cited by 30

Discovery and Optimization of 2H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer

Rohde, J. M., Surendra, K., Pragani, R., Liu, L., Fang, Y., Zhang, W., McIver, A. L., Zheng, H., Liu, Q., Davis, M. I., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00019 · Cited by 31

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma

Chen, X., Liu, J., Li, Y., Zeng, Y., Wang, F., Cheng, Z., Duan, H., Pan, G., Yang, S., Chen, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42545-3 · Cited by 30

Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives

Carosi, F., Broseghini, E., Fabbri, L., Corradi, G., Gili, R., Forte, V., Roncarati, R., Filippini, D. M., & Ferracin, M. (2024) · Cancers · doi:10.3390/cancers16152752 · Cited by 31

Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?

Braconi, C., Roessler, S. K., Kruk, B., Lammert, F., Krawczyk, M. J., & Andersen, J. B. (2019) · Liver International · doi:10.1111/liv.14085 · Cited by 31

A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3AR882) Demonstrates a Causal Relationship between Its Dominant-Negative Effect and Leukemogenesis

Lu, R., Wang, J., Ren, Z., Yin, J., Wang, Y., Cai, L., & Wang, G. G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3275 · Cited by 31

R-2HG downregulates ERα to inhibit cholangiocarcinoma via the FTO/m6A-methylated ERα/miR16-5p/YAP1 signal pathway

Gao, Y., Ouyang, X., Zuo, L., Xiao, Y., Sun, Y., Chang, C., Qin, X., & Yeh, S. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.06.017 · Cited by 30

2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies

Raimondi, V., Ciotti, G., Gottardi, M., & Ciccarese, F. (2022) · Biomedicines · doi:10.3390/biomedicines10061359 · Cited by 35

Metaboloepigenetics in cancer, immunity, and cardiovascular disease

Keating, S. T., & El‐Osta, A. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac058 · Cited by 29

Epigenetic Modifiers in Normal and Malignant Hematopoiesis

Haladyna, J. N., Yamauchi, T., Neff, T., & Bernt, K. M. (2015) · Epigenomics · doi:10.2217/epi.14.88 · Cited by 30

Enigmas of IDH mutations in hematology/oncology

Heuser, M., Cruz, M. M. A., Goparaju, R., & Chaturvedi, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.005 · Cited by 28

IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53

Jiang, B., Zhao, W., Shi, M., Zhang, J., Chen, A., Ma, H., Suleman, M., Lin, F., Zhou, L., Wang, J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001385 · Cited by 29

Contemporary outcomes in IDH ‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment

Lachowiez, C. A., Reville, P. K., Kantarjian, H. M., Jabbour, E. J., Borthakur, G. M., Daver, N. G., Issa, G. C., Furudate, K., Tanaka, T. N., Pierce, S. A., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26694 · Cited by 31

A New Frontier in Studying Dietary Phytochemicals in Cancer and in Health: Metabolic and Epigenetic Reprogramming

Shannar, A., Sarwar, M. S., & Kong, A. T. (2022) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2022.27.4.335 · Cited by 29

Online Sample Concentration in Partial‐Filling Chiral Electrokinetic Chromatography – Mass Spectrometry

Wuethrich, A., Haddad, P. R., & Quirino, J. P. (2013) · Chirality · doi:10.1002/chir.22257 · Cited by 28

The Multifaceted Metabolism of Glioblastoma

Quinones, A., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_4 · Cited by 28

Molecular and Morphological Changes Induced by Ivosidenib Correlate with Efficacy in Mutant- IDH1 Cholangiocarcinoma

Aguado-Fraile, E., Tassinari, A. M., Ishii, Y., Sigel, C., Lowery, M. A., Goyal, L., Gliser, C., Jiang, L., Pandya, S. S., Wu, B., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1274 · Cited by 28

Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China

Wang, Z., Zhang, Z., Li, Y., Sun, L., Peng, D., Du, D., Zhang, X., Han, L., Zhao, L., Lu, L., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.005 · Cited by 28

Pheochromocytoma: Gasping for Air

Jochmanová, I., Zhuang, Z., & Pacák, K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0231-4 · Cited by 30

Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1

Law, J. M., Stark, S., Liu, K., Liang, N. E., Hussain, M. M., Leiendecker, M., Ito, D., Verho, O., Stern, A. M., Johnston, S. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00264 · Cited by 28

Nickel( ii ) inhibits the oxidation of DNA 5-methylcytosine in mammalian somatic cells and embryonic stem cells

Yin, R., Mo, J., Dai, J., & Wang, H. (2018) · Metallomics · doi:10.1039/c7mt00346c · Cited by 28

Metabolic Regulation of the Epitranscriptome

Thomas, J. M., Batista, P. J., & Meier, J. L. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b00951 · Cited by 30

Oncometabolites in cancer: from cancer cells to the tumor microenvironment

Chen, L., & Huang, M. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00096-7 · Cited by 28

D-2-Hydroxyglutarate and L-2-Hydroxyglutarate Inhibit IL-12 Secretion by Human Monocyte-Derived Dendritic Cells

Ugele, I., Cárdenas-Conejo, Z. E., Hammon, K., Wehrstein, M., Bruß, C., Peter, K., Singer, K., Gottfried, E., Boesch, J., Oefner, P. J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030742 · Cited by 32

Tumor Metabolism as a Regulator of Tumor–Host Interactions in the B-Cell Lymphoma Microenvironment—Fueling Progression and Novel Brakes for Therapy

Beielstein, A. C., & Pallasch, C. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174158 · Cited by 26

Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2

Dutta, R., Zhang, T. Y., Köhnke, T., Thomas, D., Linde, M. H., Gars, E. J., Stafford, M., Kaur, S., Nakauchi, Y., Yin, R. R., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133344 · Cited by 27

Intermediary metabolism: An intricate network at the crossroads of cell fate and function

Ferreira, L. M. R., Li, A. M., Serafim, T. L., Sobral, M. C. M., Alpoim, M. C., & Urbano, A. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165887 · Cited by 27

Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies

Waitkus, M. S., & Yan, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1827 · Cited by 26

Targeting phosphoglycerate dehydrogenase in multiple myeloma

Elsaadi, S., Steiro, I. J., Abdollahi, P., Vandsemb, E. N., Yang, R. R., Slørdahl, T. S., Rø, T. B., Menu, E., Sponaas, A., & Børset, M. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00196-w · Cited by 26

Isocitrate dehydrogenase 1R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype

Whitehall, V., Dumenil, T. D., McKeone, D., Bond, C., Bettington, M. L., Buttenshaw, R. L., Bowdler, L. M., Montgomery, G. W., Wockner, L. F., & Leggett, B. (2014) · Epigenetics · doi:10.4161/15592294.2014.971624 · Cited by 26

Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q

Chen, J., Yang, J., Sun, X., Wang, Z., Cheng, X., Lu, W., Cai, X., Hu, C., Shen, X., & Cao, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-16427-w · Cited by 29

IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme

Polívka, J., Pešta, M., Pitule, P., Hes, O., Holubec, L., Polívka, J., Kubíková, T., & Tonar, Z. (2018) · Oncotarget · doi:10.18632/oncotarget.24536 · Cited by 28

IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region

Xing, Z., Zhang, H., She, D., Lin, Y., Zhou, X., Zeng, Z., & Cao, D. (2019) · Acta Radiologica · doi:10.1177/0284185119842288 · Cited by 26

The Role of Somatic Mutations in Acute Myeloid Leukemia PathogenesisPreprint

Kishtagari, A., & Levine, R. L. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034975 · Cited by 26

Mutant IDH : A Targetable Driver of Leukemic Phenotypes Linking Metabolism, Epigenetics and Transcriptional Regulation

Garrett-Bakelman, F. E., & Melnick, A. M. (2016) · Epigenomics · doi:10.2217/epi-2016-0008 · Cited by 25

Beyond JAK inhibitor therapy in myelofibrosis

Odenike, O. M. (2013) · Hematology · doi:10.1182/asheducation-2013.1.545 · Cited by 25

Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity

Cai, M., Zhao, J., Ding, Q., & Wei, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24454 · Cited by 30

Metabolism pathway-based subtyping in endometrial cancer: An integrated study by multi-omics analysis and machine learning algorithms

Liu, X., Wang, W., Zhang, X., Liang, J., Dingqing, F., Li, Y., Xue, M., & Ling, B. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102155 · Cited by 28

Unraveling the underlying mechanisms of cancer stem cells in therapeutic resistance for optimizing treatment strategies

Tan, Y., Qin, S., Zhang, Z., Liu, Y., Zhou, L., Li, B., Nice, E. C., Zhang, Y., & Jing, J. (2025) · MedComm – Oncology · doi:10.1002/mog2.70009 · Cited by 29

The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.

Karlic, H., Herrmann, H., Varga, F., Thaler, R., Reitermaier, R., Spitzer, S., Ghanim, V., Blatt, K., Sperr, W., Valent, P., et al. (2014) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2013.10.003 · Cited by 27

5-Hydroxymethylcytosine: a Potential Therapeutic Target in Cancer

Rodger, E. J., Chatterjee, A., & Morison, I. M. (2014) · Epigenomics · doi:10.2217/epi.14.39 · Cited by 25

Novel epigenetic therapies in hematological malignancies: Current status and beyond

Gallipoli, P., & Huntly, B. J. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.005 · Cited by 25

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias

Testa, U., Castelli, G., & Pelosi, E. (2020) · Cancers · doi:10.3390/cancers12092427 · Cited by 26

The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?

Cook, M. R., Karp, J. E., & Lai, C. (2021) · eJHaem · doi:10.1002/jha2.317 · Cited by 26

2-Hydroxyglutarate destabilizes chromatin regulatory landscape and lineage fidelity to promote cellular heterogeneity

Kusi, M., Zand, M., Lin, L., Chen, M., Lopez, A., Lin, C.-L., Wang, C., Lucio, N. L. L., Kirma, N. B., Ruan, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110220 · Cited by 28

Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells

Gruber, E., So, J., Lewis, A. C., Franich, R. L., Cole, R., Martelotto, L. G., Rogers, A. J., Vidacs, E., Fraser, P., Stanley, K. L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111182 · Cited by 28

R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis

Ye, D., Ma, S., Xiong, Y., & Guan, K. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.005 · Cited by 83

IDH Mutations, 2-Oxoglutarate-dependent Dioxygenases, and Leukemia

Kaelin, W. G. (2014) · Blood · doi:10.1182/blood.v124.21.sci-6.sci-6 · Cited by 1

Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate

Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A., Goparaju, R., Schwarzer, A., Görlich, K., Schottmann, R., Struys, E. A., Jansen, E. E. W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.71 · Cited by 50

Abstract IA02: Molecular pathogenesis of IDH mutant cancers and evolving treatment strategies

Kaelin, W. G. (2015) · Cancer Research · doi:10.1158/1538-7445.brain15-ia02

Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis

Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A. K., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F. R., et al. (2012) · Blood · doi:10.1182/blood.v120.21.770.770